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Abstract The clinical successes of targeting angiogenesis
provide a basis for trials of interleukin-1 (IL-1) blockade
and particularly anti-IL-1β as an add-on therapy in human
metastatic disease. In animal studies for over 20 years, IL-1
has been demonstrated to increase adherence of tumor cells
to the endothelium in vitro, and administration of IL-1 to
mice increases the number of metastatic colonies and tumor
growth. Importantly, reducing endogenous IL-1 activity,
particularly IL-1β, with the naturally occurring IL-1
receptor antagonist (IL-1Ra) reduces both metastasis as
well as tumor burden. Inhibition of IL-1 activity prevents in
vivo blood vessel formation induced by products released
from hypoxic macrophages or vascular endothelial cell
growth factor itself. Mice deficient in IL-1β do not form
blood vessels in matrigels embedded with vascular endo-
thelial cell growth factor or containing products of macro-
phages. Recombinant IL-1Ra (anakinra) has been
administered to over 1,000 patients with septic shock
resulting in a consistent reduction in all-cause 28-day
mortality. Approved for treatment of rheumatoid arthritis,
anakinra has a remarkable safety record. Anakinra resulted
in decreased blood vessels in the pannus of affected joints
in patients with rheumatoid arthritis. Neutralizing mono-
clonal antibodies to IL-1β and a soluble receptor to IL-1 are
approved for treating chronic inflammatory diseases. Given
the availability of three therapeutic agents for limiting IL-1
activity, the safety of blocking IL-1, and the clear benefit of
blocking IL-1 activity in animal models of metastasis and
angiogenesis, clinical trials of IL-1 blockade should be





1 Chronic inflammation and IL-1-mediated
carcinogenesis
Models of interleukin (IL)-1 induced carcinogenesis -
Chronic rather than acute inflammation is important in the
pathogenesis of carcinogenesis. Balkwill et al [1] and
Mantovani [2] used the expression “smoldering” inflam-
mation to indicate a local inflammatory process that is
subclinical. The role of microenvironment IL-1 has been
studied using 3-methylcholanthrene-induced carcinogenesis
in the skin. [3] In that study, IL-1β emerged as the culprit,
whereas IL-1α exerts less of a proinflammatory effect. In
the microenvironment of 3-methylcholanthrene-induced
skin carcinogenesis, tumors developed slower and only in
some of IL-1β-deficient mice compared with wild-type
mice. [3] Not unexpectedly, in mice deficient in their own
IL-1Ra and hence without opposition to endogenous IL-1,
tumor development was the most rapid. Tumor incidence
was similar in wild-type as well as in IL-1α-deficient mice.
A sparse leukocyte infiltrate was found at the site of
carcinogen injection in IL-1β-deficient mice, whereas in
IL-1Ra-deficient mice, a dense neutrophilic infiltrate was
observed. Treatment of IL-1Ra-deficient mice with recom-
binant IL-1Ra but not with an inhibitor of tumor necrosis
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DOI 10.1007/s10555-010-9229-0factor (TNFα) abrogated the early leukocytic infiltrate. The
late leukocyte infiltrate (day 70), which was dominated by
macrophages, was also apparent in wild-type and
IL-1α-deficient mice, but was nearly absent in IL-1β-
deficient mice.
Fibrosarcoma cell lines, established from tumors from IL-
1Ra-deficient mice and presumably deficient in IL-1Ra,
were more aggressive and metastatic than tumor cell lines
from wild-type mice. [3] These observations support a
general concept that in the microenvironment of chronic
inflammation, IL-1β rather than IL-1α affects carcinogenesis
and determines the invasive potential of malignant cells.
Chronic infection, IL-1β, and carcinogenesis in
humans The best example is the chronic infection with
Helicobacter pylori and gastric carcinoma. Here, there is a
strong association with the presence of IL-1β or the
regulation of the IL-1Ra. [4–7] Polymorphisms in the gene
for IL-1β and IL-1Ra are associated with an increase risk of
gastric cancer, although some studies fail to find these
associations in non-Caucasian populations. [8] Using early-
stage gastric carcinoma patients, Glas and coworkers [5]
reported that the homozygous polymorphism in the IL-1Ra
gene was strongly associated with the presence of this
early-stage tumor rather than late stage cancer (p < 0.001).
These investigators also reported that the combined poly-
morphisms in IL-1β and TNFα gene clusters are a risk for
the diffuse type of gastric carcinoma. [5] In a Korean
population, the combination of increased mucosal IL-1β
levels in H. pylori-infected patients with gastric carcinoma
and homozygosity for IL-1β -31T single nucleotide
polymorphism was associated with increased risk of gastric
cancer (odds ratio, 3.4; 95% confidence interval, 1.5–7.7).
[9]
Considering the role of IL-1 as a functional cytokine in
host defense against infection, once eliminated by anti-
biotics, infection and its accompanying inflammation are no
longer present and the “on” signal for cytokine production
becomes a rapid “off.” This mechanism limits the produc-
tion of cytokines, thereby reducing any negative effect of
cytokine-mediated inflammation. In addition to chronic
infection, the most likely regulator of the inflammatory
process is a recurring irritant. Common examples are certain
carcinogens in food, smoking, industrial carcinogens, and
ultraviolet light. Nearly all proinflammatory cytokines and
chemokines are increased by these agents. [1]
2 Proinflammatory cytokines: two sides of the same coin
Before discussing a role for IL-1 in metastasis, one must
confront the paradox of the same cytokine being both
beneficial and harmful. Mantovani uses the expression
“ying and yang” for the same concept, [10]—a concept that
is fundamental to cytokine biology. Most cytokines
function in host defense against infection; the danger of
infection is particularly a threat during the neonatal period
and early development. In contrast, with the exception of
childhood leukemia, carcinogenesis and metastasis are
characteristics of the adult and particularly in aging.
Therefore, one could view the production of a cytokine such
as IL-1 in the young host as beneficial, whereas the same
cytokine may contribute to metastasis in an elderly person.
For example, the incidence of multiple myeloma increases
with age, and the cytokines IL-1 and IL-6 are growth,
survival, and proangiogenic factors for the myeloma cell.
Indeed, blockingIL-1inpatientswithsmolderingorindolent
myeloma reduces IL-6 production and prolongs progression-
free survival. [11] Proinflammatory cytokines possess
several properties that can be considered beneficial to the
host when challenged with invasion from bacteria and other
microorganisms in the immediate environment. An IL-1-
mediated increase in adhesion molecules on the endotheli-
um certainly facilitates the emigration of neutrophils into
the tissues, which are an absolute requirement for killing of
bacteria. The same IL-1-mediated increase in endothelial
adhesion molecules facilitates the metastatic process. [12]
3 IL-1 and metastasis
As reviewed in Lewis et al., [13] IL-1 expression is
elevated in human breast, colon, lung, head and neck
cancers, and melanomas, and patients with IL-1 producing
tumors have generally bad prognoses. Due to the pleiotro-
pic nature of IL-1, there are several likely mechanisms on
how IL-1 promotes tumor growth and metastasis. For
example, IL-1 induces several prometastatic genes such as
matrix metalloproteinases and endothelial adhesion mole-
cules as well as vascular endothelial cell growth factor
(VEGF), chemokines, growth factors, and TGFβ.
Two mouse studies from 1990 demonstrated that a single
low dose of IL-1 but not IL-6 administered just before an
intravenous injection of tumor cells would increased the
numbers of lung metastasis. [14, 15] These and other
studies are consistent with the concept that IL-1 stimulates
the expression of endothelial adhesion molecules such as
intercellular adhesion molecule-1 (ICAM-1) and vascular
adhesion molecule-1 (VCAM-1) as well as prostaglandin
E2 [16, 17] and enhances adherence of tumor cells.
However, in some studies, the adherence of tumor cells
was independent of endothelial cell adhesion molecules but
rather on RGD.[15] Using intravital videomicroscopy,
IL-1α pretreatment arrested tumor passage in the liver,
enhancing metastasis via RGD, E-selectin, ICAM-1,
VCAM-1, and α-V integrin subunit.[18] In human mela-
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adhesion to endothelial cells and in vivo increased retention
in the lung.[19] Lung metastasis is commonly studied using
intravenous injection of tumor cells, but metastasis has also
been studied in the liver. Injection of tumor cells increases
hepatic cell gene expression for IL-1 within 4 to 6 h, and
this is followed by increased expression of E-selectin by the
hepatic sinusoidal endothelial cells.[20] Local metastasis to
the liver can be observed when melanoma cells are injected
into the spleen, in which case, IL-1 also increases the
metastatic spread.[21] However, in the case of human
melanoma cells, there is also a role for expression of
integrin VLA-4 of the tumor cells in order to adhere to
endothelial cells.[22, 23]
Tumor cells expressing the IL-1β precursor must first
activate caspase-1 in order to process the inactive precursor
into active cytokine. Activation of caspase-1 requires autoca-
talysis of procaspase-1 by the nucleotide-binding domain and
leucine-rich repeat containing protein 3 (NLRP3) inflamma-
some. [24] In late-stage human melanoma cells, spontaneous
secretion active IL-1β is observed via constitutive activation
of the NLRP3 inflammasome. [25] Unlike human blood
monocytes, these melanoma cells require no exogenous
stimulation. In contrast, NLRP3 functionality in intermediate
stage melanoma cells requires activation of the IL-1 receptor
by IL-1α in order to secrete active IL-1β. The spontaneous
secretion of IL-1β from melanoma cells was reduced by
inhibition of caspase-1 or the use of small interfering RNA
directed against the inflammasome component ASC. [25]
Supernatants from melanoma cell cultures enhanced macro-
phage chemotaxis and promoted in vitro angiogenesis, both
prevented by pretreating melanoma cells with inhibitors of
caspases-1 or IL-1 receptor blockade. [25] These findings
implicate IL-1-mediated autoinflammation as contributing to
the development and progression of human melanoma
option for melanoma patients. Whereas highly metastatic
human melanoma secrete active IL-1β including proangio-
genic properties, [25] transducing tumor cells with mature
IL-1β linked to a signal peptide results in a highly invasive
local tumor and mtea to the lung following intravenous
injection. [26] In spleens of mice injected with IL-1β and
transfectants, immunosuppression was observed. In contrast,
in tumors expressing membrane IL-1α, reduced tumorige-
nicity was observed due to antitumor immunity. [26]
Blocking endogenous IL-1 reduces metastasis Although
IL-1 will increase tumor cell metastasis, proof of this
concept comes from studies in which metastasis is reduced
with blockade of endogenous IL-1 or in mice deficient in
IL-1. The first study of this quality was reported in 1993
when treatment of mice with IL-1Ra markedly inhibited the
augmentation of lung metastasis to the human melanoma
cell A375M in mice treated with endotoxin. [27] Similar
findings have been reported for melanoma metastasis where
a complete inhibition of lipopolysaccharide augmented
hepatic metastasis by IL-1Ra was observed. [12] Using
IL-1 itself to augment metastasis, the amount of IL-1Ra was
200-fold greater that IL-1. [27] IL-1Ra treatment also
reduced the expression of ICAM-1 and VCAM-1. In a
model of hepatic metastasis, a single injection of IL-1Ra
reduced tumor colonies by 50% and tumor volume by 70%.
[21] The importance of these studies using a single dose of
IL-1Ra is the remarkable short half-life of IL-1Ra in the
mouse and the relatively prolonged effect of a short time of
IL-1RI blockade. Even when a single dose was given after
the tumor cell, there was reduced tumor volume by 58% but
with 10 daily doses; hepatic metastasis was reduced 80%.
[21] These studies reveal a role for endogenous IL-1 in the
metastatic process. However, in a model of melanoma bone
metastasis, neutralizing antimouse IL-1α antibodies did not
reduce metastasis [16].
Human melanoma cells producing high levels of
constitutive IL-1α were virally transduced with IL-1Ra
and injected into athymic mice. In vitro, proliferation of
the IL-1Ra-transduced cells was lower compared with the
same cell line transduced with the empty vector. [28]
In vivo, the IL-1Ra-expressing melanoma cells exhibited
fewer metastases. In a screen of human melanoma tumor
samples, copy number greater than 1,000 for IL-1β was
present in 14 of 16 biopsies, whereas none expressed IL-
1α.[ 29] Similar findings were observed for colon
carcinoma and non-small cell lung carcinoma. In contrast,
melamoma cell lines express IL-1α and not IL-1β.T u m o r
supernatant from these cell lines produced a significant
increase in endothelial cell monolayer permeability, a
hallmark of early angiogenesis, in an IL-1-dependent
manner. [29] When injected subcutaneously into athymic
mice, administration of IL-1Ra reduced tumor growth of
IL-1-expressing tumors but not of tumors without consti-
tutive IL-1 production. [29] When injected intravenously,
significantly fewer lung metastases were present 35 days
later. Gene expression in tumors taken from mice treated
with IL-1Ra revealed lower levels of 100 genes, and
steady-state gene expression for IL-8 was reduced 5-fold.
VEGF gene expression was markedly reduced in tumors of
mice treated with IL-1Ra. [29] Taken together, human and
murine melanoma cells appear particularly dependent on
IL-1 for invasiveness and proliferation. As reviewed
below, there is also a strong case for IL-1 in melanoma-
associated angiogenesis.
4 IL-1-mediated angiogenesis
No one doubts that angiogenesis and inflammation are
linked and pivotal processes in the progression of many
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emerges from the milieu of chronic inflammation, proin-
flammatory cytokines are exploited to provide mechanisms
for tumor cell expansion by inducing growth factors from
stromal cells such as IL-6 and fibroblast growth factor
(FGF). Next, cytokines are used to stimulate angiogenesis.
In the case of IL-1, several studies provide evidence that
angiogenesis and vascular endothelial growth factor
(VEGF) is IL-1 dependent. [26, 29–32] Nylon disks
impregnated with either basic FGF or VEGF were
implanted into one cornea of rats and then treated with
IL-1 (anakinra) or TNFα (soluble receptors) blockade for
7 days. IL-1 blockade dose-dependently reduced corneal
angiogenesis, whereas TNFσ blockade had no effect. [32]
In humans with rheumatoid arthritis, daily anakinra reduces
the number blood vessel in the pannus. [33]
In IL-1β-deficient mice, local tumor growth or lung
metastases of murine melanoma cells were not observed
compared with wild-type mice. [30] Angiogenesis into
matrigel plugs containing the melanoma cells was absent in
the IL-1β-deficient mice and also reduced in IL-1α-
deficient mice but not as impressively as in IL-1β-
deficient mice. The incorporation of IL-1Ra into
melanoma-containing plugs in wild-type mice inhibited
the ingrowth of blood vessel networks. [30] These effects
of host-derived IL-1α and IL-1β were not restricted to the
melanoma model, but were also observed in DA/3
mammary and prostate cancer cell models. [30] In addition
to the in vivo findings, IL-1 contributed to the production of
VEGF and TNFα in cocultures of peritoneal macrophages
and tumor cells. [30]
The hypoxic microenvironment of rapidly growing
tumors often results in a milieu of proinflammatory and
proangiogenic cytokines produced by infiltrating cells.
Macrophages under hypoxic conditions promote angiogen-
esis by production of several angiogenic factors. How much
of hypoxia-induced angiogenesis is IL-1 dependent? Using
mouse macrophages subjected to hypoxic conditions,
supernatants were incorporated into Matrigel plugs and
implanted into mice. Neutralization of IL-1 in the super-
natants, particularly IL-1β, completely abrogated cell
infiltration and angiogenesis. [31] When explanted, the
matrigel plugs contained 85% less VEGF. Similarly, super-
natants from macrophages of IL-1β-deficient mice did not
induce inflammatory or angiogenic responses. There were
no inflammatory responses in the recipient mice deficient in
IL-1 receptors. Myeloid cells infiltrating into Matrigel plugs
were of bone marrow origin and represented the major
source of IL-1 and other cytokines/chemokines in the plugs.
Cells of endothelial lineage were the main source of VEGF
and were recruited mainly from neighboring tissues, rather
than from the bone marrow. Using the aortic ring sprouting
assay, IL-1 does not directly activate endothelial cell
migration, proliferation, and organization into blood
vessel-like structures, but rather activates infiltrating cells
to produce VEGF. Thus, targeting IL-1β has the potential
to inhibit angiogenesis in pathological situations and may
be of considerable clinical value.
5 Are endogenous IL-1Ra levels sufficient to suppress
the prometastatic effects of IL-1?
IL-1Ra versus IL-1β in health The naturally occurring IL-1
receptor antagonist (IL-1Ra) present in the circulation of
healthy subjects is in considerable excess to IL-1β. Because
of the large body of evidence that IL-1, and particularly IL-
1β, significantly contributes to the metastatic process, the
concept that endogenous levels of IL-1Ra may be sufficient
to oppose the activities of IL-1. Using standard enzyme-
linked immunosorbent assay (ELISA) or specific radioim-
munoassay, the levels in healthy subjects are between 200
and 400 pg/ml. Others report healthy subjects with levels
150–180 pg/ml/ml (median, 387 pg/ml). [34] The manu-
facturer of the most commonly used ELISA for IL-1Ra
reports a mean serum level of 220 pg/ml, and in another
study of serum in healthy subjects, the mean level was
313 pg/ml (range, 270–360 pg/ml). [35] In general,
multiplex assays for IL-1Ra show a wider range (62–
4,300 pg/ml), although the correlation between the ELISA
and multiplex assays is significant. [35] In contrast, IL-1β
is rarely found in the circulation in health. In fact, using a
specific antibody to human IL-1β (canakinumab), the total
daily production of IL-1β was calculated to be approxi-
mately 6 ng/day. [36] In humans injected with endotoxin,
the levels of IL-1β are below detection (less than 2 pg/ml/
ml) before and elevated for a brief time (2 h) reaching
maximal concentrations of 50 to 60 pg/ml. [37] At the same
time, the elevations in IL-1Ra are 6,000 pg/ml/ml or 100-
fold greater. [37] Similar levels were reported in another
study in healthy subjects injected with endotoxin intrave-
nously. [38] Understandably, many infectious diseases and
autoimmune diseases are associated with elevated levels of
IL-1Ra, but IL-1 itself is a potent inducer of IL-1Ra. In
humans injected with increasing doses of IL-1α or IL-1β,
the rise in endogenous IL-1Ra was dramatic and observed
within 1 hour following a 15-min infusion of either IL-1α
or IL-1β.[ 39] IL-4 given to humans as part of anticancer
treatment is also an inducer of IL-1Ra. [40]
Most in vitro studies on IL-1Ra production are from
myeloid cells, but it is doubtful if the serum levels of
endogenously produced IL-1Ra are of myeloid origin.
Rather, serum IL-1Ra likely represents hepatic production
as IL-1Ra is an acute phase protein produced by the liver.
[41] Like other acute-phase proteins from the liver, IL-6
induces IL-1Ra and the combination of IL-1β plus IL-6 is
320 Cancer Metastasis Rev (2010) 29:317–329particularly effective in inducing IL-1Ra from hepatocytes.
[41] In several studies, circulating IL-1Ra correlates with
circulating IL-6. In mice with a specific deficiency in IL-
1Ra from myeloid cells, a severe form of arthritis develops.
[42] However, the level of IL-1Ra in the affected joints is
high suggesting that nonmyeloid sources of IL-1Ra
contribute to the circulating levels.
Circulating IL-1Ra in cancer Elevated serum IL-1Ra, when
significantly elevated above those in cohorts of healthy
subjects, can be associated with greater disease severity
such as larger tumor burden or metastatic spread (see
Table 1). In women with estrogen-receptor negative breast
cancer, an elevated level of IL-1Ra is associated with a
negative prognosis since the presence of estrogen receptors
is considered a positive prognostic factor. [43] As shown in
Table 1, there is no dearth of reports in various cohorts of
patients showing elevated IL-1Ra levels in different
cancers. Although most of the reports contain serum levels
of IL-1Ra as determined by a specific ELISA or multiplex
assays, there are polymorphisms in IL-1RN that influence
the circulating levels of IL-1Ra. For example, within IL-
1RN, there are variable numbers of tandem repeats
comprising 86 base pairs. Allele 2 contains two repeats
and is associated with increased circulating levels of IL-
1Ra. In a study of 885 patients with lung cancer and 1,024
matched controls without cancer, there was a clear decrease
risk in carriers of allele 2, particularly in nonsmokers. [44]
In carriers of the T/T allele single nucleotide polymorphism
(SNP) in IL-1RN, there is also an increase level of
circulating IL-1Ra [45] and an association with greater
survival with colorectal cancer. [46] In contrast, carriers of
the C/C allele exhibit lower levels of circulating IL-1Ra and
have lower survival rates. [46] In the above study of 180
patients, median survival in carriers of C/C was 28 months;
of C/T, 29.6 months, and of T/T, 35 months. [46]
Elevated levels can also be associated with less disease
compared with patients with the same disease. In this context,
a lower level ofIL-1Ra may reflect reduced inflammationdue
to a lower tumor burden or fewer metastatic lesions. It will
remain a matter of discussion whether a high level of IL-1Ra
is functional, that is, inhibits the proinflammatory properties
of IL-1β in metastasis. One can argue that since IL-1α or IL-
1β stimulates IL-1Ra production, a lower level of IL-1Ra
reflects less functional IL-1 due to inhibition of IL-1
signaling. The counterargument is that reduced IL-1 produc-
Elevated levels associated with greater disease severity
Postsurgical sepsis [75]
Survival ovarian arcinoma
Chronic fatigue in breast cancer [76]
Tumor extent in bone sarcoma [77]
Pelvic metastasis in cervical cancer [78]
Tumor load in childhood leukemia [79]
Malignant histiocytosis [80]
Hairy cell leukemia [81]
Tumor size and metastases and colorectal cancer [82–84]
Testicular cancer-related fatigue [85]
Thyroid cancer [86]
Pancreatic cancer [87]
Estrogen receptor breast cancer [43]
Elevated levels associated with lesser disease severity
Pancreatic carcinoma [88]
aColorectal carcinoma [46]
Metastatic gastric cancer [89]
cOvarian carcinoma [90]
dLung carcinoma [44]
Low levels associated with greater disease severity
Acute myelogenous leukemia [49, 91]





Table 1 Associations of levels
of IL-1Ra in cancer
aBased on IL-1Ra SNIP 4251961
TT allele
bBased on IL-1Ra SNIP 4251961
CC allele
cAscites levels were measured
dIn patients with allele 2 of
IL-1RN
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conclusion in either case is that IL-1Ra is at best, a marker for
inflammation in cancer.
6 A hypothesis derived from circulating IL-1Ra levels
in cancer
As shown in Table 1, there are examples of low levels of
IL-1Ra associated with active and even severe disease. One
can argue that low levels fail to provide sufficient
suppression of the activity of endogenous IL-1. Thus, one
can hypothesize that endogenous IL-1Ra serves a protective
function. Unlike the examples described Table 1 showing
high levels of IL-1Ra associated with severe disease, low
IL-1Ra levels do not reflect an inflammatory response since
there would be more IL-1Ra given the greater amount of
cancer. Having lower levels of IL-1Ra associated with
greater disease severity suggests that IL-1Ra production is
insufficient to counter the prometastatic properties of IL-1β.
Indeed, this is the case with acute or chronic myelogenous
leukemia where low or near-absent IL-1Ra production is
associated with greater leukemic burden. [47–49] A similar
case can be made for other tumors, although the hypothesis
is best appreciated in hematopoietic cancers such as
lymphoma, Hodgkin's disease, multiple myeloma, and
acute and chronic leukemias. In these diseases, constitutive
cell production of IL-1β is high, whereas IL-1Ra is low.
Therefore, from these cancers, one could conclude that
blocking IL-1β would provide for reduced disease.
The concept that there is insufficient endogenous IL-1Ra
to counter the proinflammatory properties of IL-1 has both
animal as well as human examples. Rabbits passively
immunized against their own endogenous IL-1Ra exhibit
a worsening of colitis [50] and mice deficient in IL-1Ra
developed spontaneous diseases such as a destructive
arthritis, [51] an arteritis, [52] and a psoriatic-like skin
eruption. Furthermore, mice deficient in endogenous IL-
1Ra develop an aggressive tumors following exposure to
carcinogens. [3] These data support the concept that the
relative amounts of IL-1 versus IL-1Ra affect the severity
of some diseases. A SNP C allele is associated with lower
circulating levels of IL-1Ra [45, 53] with a concomitant
increase in type 2 diabetes. [53] As stated above, the same
polymorphism is associated with reduced survival in
patients with colon carcinoma compared with those with
the wild-type allele. [46]
The concept of an imbalance between IL-1β and IL-1Ra
gained considerable legitimacy with reports of infants born
with a genetic basis for nonfunctional IL-1Ra. [54, 55]
Soon after birth, the affected infants exhibited impressive
systemic and local inflammation. Unless treated with
exogenous IL-1Ra, the infants die. Multiple neutrophil-
laden pustular skin eruptions, vasculitis, bone abnormalities
with large numbers of osteoclasts, osteolytic lesions, and
sterile osteomyelitis were observed. The inflammation
resembled infection with sepsis-like multiorgan failure,
but all cultures were sterile. When treated with daily
anakinra, the inflammation abates and the bone lesions
reverse. IL-17 was prominently expressed in cells from
these patients (see below). These findings are an extreme
example that without functional IL-1Ra, the activity of
endogenous IL-1 is “unopposed” and IL-1-driven inflam-
mation can run rampant. One can conclude that low levels
of IL-1β can induce inflammation, but the presence of
natural IL-1Ra is sufficient to limit the inflammation.
IL-1Ra is found in the circulation of healthy subjects in
the range of 200 to 300 pg/ml, whereas IL-1β is in the low
picogram per milliliter range and is not easily detectable by
standard ELISA methods in the same individuals. In
healthy humans, daily constitutive production of IL-1β
w a sc a l c u l a t e da t6n g ;i np a t i e n t sw i t hc r y o p y r i n -
associated periodic syndromes (CAPS), a rare genetic
disease due to IL-1β production was calculated at 31 ng/
day. [36] These calculations are consistent with reports of
increased release of IL-1β from blood monocytes of
patients with autoinflammatory diseases. The increase is
usually 5- to 10-fold more than that from blood monocytes
of healthy subjects. [56–58]
7 IL-1 in multiple myeloma
Anakinra in a clinical trial Support for this concept comes
from studies of IL-1Ra treatment of patients with an
evolving progression from a benign condition called
monoclonal gammopathy of unspecified significance.
Monoclonal gammopathy of unspecified significance and
smoldering myeloma present a challenge to medicine as the
population ages. [59] Several years of research has focused
on the role of IL-1β and IL-6 in the pathogenesis of
multiple myeloma. [60, 61] Similar to mature B cells, the
myeloma plasma cell produces IL-1β. In the microenvi-
ronment of the bone marrow, stromal cells respond to low
concentrations of IL-1β and release large amounts of IL-6,
which in turn promotes the survival and expansion of the
myeloma cells. Although IL-6 is an essential growth factor
for myeloma cells, antibodies to IL-6 have not been
effective in treating the disease, perhaps because the
therapy is initiated too late in overt multiple myeloma.
Lust et al. [11] reasoned that in the indolent stages of
multiple myeloma, blocking IL-1β would provide better
reduction of IL-6 activity. Bone marrow cells from patients
with smoldering myeloma were cocultured with a myeloma
cell line actively secreting IL-1β. Although the addition of
dexamethasone reduced stromal cell IL-6 production, the
322 Cancer Metastasis Rev (2010) 29:317–329amount of IL-6 remained sufficiently high enough to
protect the plasma cell against dexamethasone-mediated
apoptosis. However, anakinra added to these cocultures
significantly reduced IL-6 by nearly 90% and the combi-
nation of anakinra plus dexamethasone induced myeloma
cell death.
Patients with smoldering or indolent myeloma were
selected with the clinical objective of slowing or preventing
progression to active disease. Based on in vitro data, 47
patients with smoldering/indolent myeloma at high risk for
progression to multiple myeloma were treated with daily
anakinra for 6 months. During the 6 months, there were
decreases in C-reactive protein (CRP) in most but not all
patients, which paralleled a decrease in the plasma cell
labeling index, a measure of myeloma cell proliferation in
unfractionated bone marrow cells. After 6 months of
anakinra, a low dose of dexamethasone (20 mg/week) was
added. Of the 47 patients that received anakinra (25 with
dexamethasone), progression-free disease was over 3 years
and in 8 patients over 4 years [11] compared with historical
experience; the findings indicate a significant failure to
progress to active disease and a modest fall in CRP
predicted responders who continued with stable disease.
Patients with a decrease in serum CRP of 15% or greater
after 6 months of anakinra monotherapy resulted in
progression-free disease greater than 3 years compared
with 6 months in patients with less than a 15% fall during
anakinra therapy (p<0.002). Thus, an effective reduction in
IL-1β activity using CRP as the marker for IL-1β-induced
IL-6 halts progression to active myeloma.
Angiogenesis in multiple myeloma Angiogenesis plays a
pathological role in multiple myeloma. As discussed above,
there are a growing number of reports on IL-1β as a key
cytokine in angiogenesis [25, 26, 30–32, 62]. Compared
with thalidomide or its analogues, blocking IL-1β is
essentially free of toxic side effects. There is an ongoing
National Institutes of Health trial of anakinra as an
antiangiogenic therapy in patients with cutaneous melano-
ma. Because blocking IL-1β reduces IL-6 as well as the
proangiogenic chemokine IL-8, the use of IL-1β blocking
strategies may result in therapy in high-risk patients with
smoldering/indolent myeloma or metastatic melanoma.
There is also a role for IL-1β in the angiogenic process of
macula degeneration, [63] and anakinra treatment in
rheumatoid arthritis reduces the vascularization of the
pannus. [33]
8 Blocking IL-1β in metastatic disease in humans
Does blocking IL-1β interfere with an immunologically-
mediated anti-tumor effect? In mouse models, IL-1α
expression on tumor cells can provide an immunologic
stimulus such that there is reduce tumor progression. The
data are derived from expression of IL-1α on tumor cells
themselves and in such models, IL-1α remains cell
associated, as an intergral membrane protein or intracellu-
larly as a precursor. As reviewed by Apte et al, [64] IL-1 is
abundant at tumor sites but membrane-associated IL-1α
expressed on malignant cells stimulates antitumor immuni-
ty, whereas secreted IL-1β, derived from the microenvi-
ronment macrophages or the malignant cells, activates
inflammation, which in turn promotes invasiveness. In
addition, IL-1β but also induces tumor-mediated suppres-
sion. [26, 65]
Oncogene-transformed fibroblasts, which expressed IL-
1α, spontaneously regress in their syngeneic host. [66]
Regression is significantly influenced by the immune
competence of the host and is T-cell-mediated. Frequencies
of cytotoxic T-cell precursors were significantly increased
after in vivo immunization with IL-1-expressing as com-
pared with IL-1-nonexpressing transformed fibroblasts. IL-
1α expression of transformed fibroblasts plays an important
role in the induction of a T-cell-mediated antitumor
response. As such, a justacrine effect takes place in which
membrane IL-1α attracts immunocompetent cells to the
tumor site and assists in an immunologic response that
combats tumor growth. This model also serves as the basis
for anticancer vaccines, as IL-1 functions as an adjuvant.
Understandably, blocking IL-1 activity may seem counter-
productive in a proposed use in cancer patients. However,
in the same mouse models in which a beneficial effect of
IL-1α can be demonstrated, blocking IL-1β reduces the
metastatic spread of tumors.
Regardless of source of inflammation, a persistent local
inflammatory process draws inflammatory cells in much the
same way a chronic local infection. [67] The persistence of
the inflammatory trigger may come from secretion of IL-1β
but also from IL-1α released from necrotic tumor cells.
Intracellular IL-1α is a chromatin-associated cytokine and
highly dynamic in the nucleus of living cells. [68] During
apoptosis, IL-1α concentrates in dense nuclear foci. This
event markedly reduces its mobile nature of the IL-1α
precursor, and being retained within the chromatin fraction
is not released along with the cytoplasmic contents. In
contrast, cells undergoing necrosis release their contents
and when incorporated in matrigels, recruit cells of the
myeloid lineage, whereas lysates of necrotic cells lacking
IL-1α failed to recruit an infiltrate. [68] When normal
keratinocytes are subjected to hypoxia, the constitutive IL-
1α precursor is released into the supernatant and recruits
myeloid cells via an IL-1α-dependent process. [68] Thus,
after an ischemic event, which may take place in rapidly
growing tumors, the IL-1α precursor is released by hypoxic
cells and incites an inflammatory response by recruiting
Cancer Metastasis Rev (2010) 29:317–329 323myeloid cells into the area. As such, blocking IL-1α in such
situations may be equally effective in reducing
inflammation-induced angiogenesis and metastasis.
9 Therapeutic options for treating metastatic disease
with IL-1 blocking agents
Current status of use of IL-1 blocking therapeutics in
human diseases As listed in Table 2, several IL-1 blocking
agents are used successfully in various chronic as well as
inflammatory diseases. There are over 30 trials listed in
clinicaltrials.gov with IL-1 blocking agents. One trial listed
is the use of anakinra in patients with IL-1 producing
melanoma, but the results of this trial are not published.
Some chronic inflammatory diseases are successfully
treated with neutralization by human anti-IL-1β monoclo-
nal antibodies, for example, in type 2 diabetes, either
anakinra or a monoclonal antibody to IL-1β improve
glycemic control. [53, 69, 70] At this writing, one anti-IL-
1β antibody (canakinumab) has been approved for treating
CAPS, [71] whereas others are presently in clinical trials.
Rilonacept is a construct of the two extracellular chains of
the IL-1 receptor complex (IL-1RI plus IL-1RAcP) fused to
the Fc segment of IgG and has been approved for use in
CAPS. [72]
There are two important considerations for using IL-1
blocking agents in the treatment of metastatic disease and
particularly in reducing angiogenesis. First, there are no
known organ toxicities. The use of anakinra in patients with
rheumatoid arthritis exceeds over 200,000, and many are
being treated for over 5 years. Rilonacept and canakinumab
have also not been associated with any organ toxicities,
gastrointestinal, or hematologic abnormalities. Essentially,
there is no maximum tolerated dose for IL-1 blocking
agents. Second, although routine bacterial infections and
upper airway infections are increased in patients treated
with IL-1 blocking agents, unlike other biologicals such as
TNFα blocking treatments, there have been no opportu-
nistic infections. The disadvantage of anakinra is the short
plasma half-life (4 hours) necessitating daily injections.
The injections are associated with injection site reactions,
which subside in most cases after a few weeks. However,
the advantage of anakinra is the rapid decrease in the
body such that stopping treatment can be necessary when
infections develop. Also, anakinra blocks the IL-1 receptor
and hence reduces the activity of IL-1α as well as IL-1β.
This is not the case with monoclonal antibodies to IL-1β.
The advantage of anti-IL-1β monoclonal antibodies is the
long biological half-life and once-a-month dosing. Rilo-
nacept is intermediate and may neutralize IL-1α on the
cell surface.
Trial design options Anti-VEGF (bevacizumab) is often
added to standard chemotherapy and has resulted in
improved survival in colorectal and lung cancer patients
and progression-free survival in breast cancer patients. [73]
Inhibition of VEGF receptor signaling by tyrosine kinase
inhibitors also results in survival benefit. [74] However,
bevacizumab used in combination vatalanib, a kinase
inhibitor, did not show a benefit. [73] The question is
how best to combine IL-1 blocking agents with either anti-
VEGF or anti-VEGF receptors or kinase inhibitors.
The best trial design option is to add IL-1 blocking
therapies to standards of therapy. In the case of monoclonal
antibodies to VEGF or antibodies to VEGF receptors,
adding an IL-1 blocking agent may increase the antiangio-
genic efficacy without increasing the toxic side effects.
Alternatively, adding an IL-1 blocking therapeutic may
allow the use of a lower dose of anti-VEGF or antibodies to
VEGF receptors in order to reduce the toxicities associated
with these monoclonal antibodies. The dose-limiting tox-
icities of bleeding, thrombosis, hypertension, hypothyroid-
ism, proteinuria, edema, and skin lesions associated with
antibodies to VEGF or its receptors [74] are unlikely to
occur with IL-1 blockade. Small molecule inhibitors of
Table 2 IL-1 blockade in the treatment of inflammatory diseases
a
Classic autoinflammatory diseases
Familial Mediterranean fever [95–97]
CAPS
b [57, 71, 72, 98]
Hyper-IgD syndrome, mevalonic aciduria [99–101]
Adult and juvenile Still's disease [56, 102–105]
Behçet's disease [106]
Schnitzler's syndrome [107–109]
TNF receptor-associated periodic syndrome [110–112]
PAPA syndrome; Blau's syndrome; Sweet's syndrome [113]
Probable autoinflammatory diseases




Common diseases mediated by IL-1β
Urate crystal arthritis (gout) [119–123]
Type 2 diabetes [53, 69, 70]
Smoldering multiple myeloma [11]
Postmyocardial infarction heart failure [124]
Osteoarthritis [125]
aEach responsive to reduction in IL-1β activity
bCAPS is a grouping of familial cold autoinflammatory syndrome,
Muckle-Wells syndrome, and neonatal onset multi-inflammatory disease
PAPA pyogenic arthritis, pyoderma gangrenosum, and acne
324 Cancer Metastasis Rev (2010) 29:317–329VEGFR1, VEGFR2, VEGFR3, basic FGF, PDGFR, and
other tyrosine kinase inhibitors have similar unwanted side
effects, and their doses may be reduced with anti-IL-1-
based therapies without sacrificing efficacy.
The possibility of reducing immunosurveillance associ-
ated with the use of “biologicals” to treat autoimmune
diseases is a common concern. Although there is increasing
evidence that there may be an increase in lymphoma
associated with anti-TNFα therapies, this association is
observed in patients with known increased incidence of
hematopoietic cancers before the introduction of biologicals
to treat autoimmune diseases. To date, there are no
associations of increased malignant disease with IL-1
blocking agents, although by comparison, the numbers of
patients receiving anakinra are low compared with those
being treated with TNFα blocking therapies. Moreover,
patients with autoimmune diseases are treated continuously
with TNFα blocking agents, whereas treatment of meta-
stastic disease with IL-1 blockers would likely be in cycles.
In mouse models of tumor-associated immunosuppression,
blocking IL-1β improves immunoresponsiveness. [26, 65]
10 Summary
Anakinra is safe and has been administered to thousands of
patients in controlled trials in patients with active infections,
chronic inflammatory diseases, and acute inflammatory
diseases such as gout and ischemic central nervous cerebro-
vascular accidents, each with improvement and few if any
side effects. High levels (20 µg/ml) can be obtained with
infusion rates of 1 and 2 mg/kg/hour for 72 hours and can
likely be administered for longer time periods. Thus, trials for
adding anakinra to standards of therapies in patients with
metastasesseemdoable.Inparticular,addingIL-1blockadeto
antiangiogenic based therapies may increase efficacy or
reduce the toxic side effects such as hypertensive complica-
tions. Anakinra has a remarkable safety record, and in over
250,000 patients, anakinra is not associated with increased
susceptibility to Mycobacterium tuberculosis or other oppor-
tunistic infections compared with other “biologicals,” partic-
ularly to anti-tumor necrosis factor (TNFα). In addition to
anakinra, neutralizing monoclonal antibodies to IL-1β and a
soluble receptor to IL-1 are approved for treating chronic
inflammatory diseases.
There is no dearth of animal studies supporting trials for
blocking IL-1 activity in cancer. IL-1 increases adherence
of tumor cells to the endothelium in vitro via enhanced
expression of E-selectins, RGD, integrins, and adhesion
molecules; moreover, administration of IL-1 to mice
increases the number of metastatic colonies and tumor
growth. Importantly, reducing endogenous IL-1 activity,
particularly IL-1β, reduces both metastasis and tumor
growth. The most compelling argument for IL-1 blockade
is the key role for IL-1 in angiogenesis. IL-1 is a potent
proangiogenic cytokine, and inhibition of IL-1 activity
prevents in vivo blood vessel formation induced by VEGF
itself. Mice deficient in IL-1β do not form blood vessels in
matrigels embedded with VEGF or containing products
released from stimulated macrophages.
11 Conclusions
Preclinical evidence provides ample support for reducing
IL-1 activity in treating human metastatic disease. The
availability of three safe therapeutic agents to block IL-1
activity in humans provides a unique opportunity to
increase the efficacy of angiogenesis-targeting agents and
or reduce the toxic side effects of these therapies without
sacrificing their benefits.
12 Key unanswered questions
1. Will blocking IL-1 activity alone reduce metastatic
disease in humans?
2. Will the combination of IL-1 blockade with antiangio-
genic antibodies or small molecules improve their
efficacy?
3. Will the combination of IL-1 blockade with antiangio-
genic antibodies or small molecules reduce their side
effects?
4. Will blocking IL-1 activity reduce tumor surveillance
or antitumor immune mechanisms?
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